Paul Damon & Associates, Inc. Eli Lilly & CO Transaction History
Paul Damon & Associates, Inc.
- $209 Billion
- Q3 2025
A detailed history of Paul Damon & Associates, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Paul Damon & Associates, Inc. holds 610 shares of LLY stock, worth $623,237. This represents 0.22% of its overall portfolio holdings.
Number of Shares
610
Previous 467
30.62%
Holding current value
$623,237
Previous $364 Million
27.85%
% of portfolio
0.22%
Previous 0.19%
Shares
3 transactions
Others Institutions Holding LLY
# of Institutions
4,500Shares Held
754MCall Options Held
14.9MPut Options Held
16.9M-
Lilly Endowment Inc Indianapolis, IN95.5MShares$97.6 Billion0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA81MShares$82.7 Billion0.96% of portfolio
-
Black Rock Inc. New York, NY65.9MShares$67.3 Billion1.37% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA51.4MShares$52.5 Billion24.16% of portfolio
-
State Street Corp Boston, MA34.7MShares$35.5 Billion0.95% of portfolio
About ELI LILLY & Co
- Ticker LLY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 950,174,976
- Market Cap $971B
- Description
- Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...